Prosecution Insights
Last updated: August 06, 2026

Shenghe (China) Biopharmaceutical Co. Ltd.

4 pending office actions • 0 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Portfolio Summary

4
Total Pending OAs
4
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (50%)
2
Medium (50%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other2 (50%)
Double-patenting + other2 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

0
Life Sciences
0% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
4
Business / Other
100% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
CARTER, SANDRA DILLAHUNT 1 56.1% +29.7%
CHEONG, CHEOM-GIL 1 65.0% +54.0%
LUNDE, GRACE HENRY 1 63.0% +38.9%
LEE, YIE CHIA 1 71.9% +45.6%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18576215 ANTI-CD24 ANTIBODY AND USE THEREOF LUNDE, GRACE HENRY
18569312 ANTI-TNFR2 ANTIBODY AND PREPARATION METHOD AND APPLICATION THEREOF LEE, YIE CHIA

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18293500 MULTISPECIFIC ANTIGEN-BINDING PROTEIN AND USE THEREOF CARTER, SANDRA DILLAHUNT
18293515 MULTISPECIFIC ANTIGEN-BINDING PROTEIN AND USE THEREOF CHEONG, CHEOM-GIL
18576215 ANTI-CD24 ANTIBODY AND USE THEREOF LUNDE, GRACE HENRY
18569312 ANTI-TNFR2 ANTIBODY AND PREPARATION METHOD AND APPLICATION THEREOF LEE, YIE CHIA

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18293500 MULTISPECIFIC ANTIGEN-BINDING PROTEIN AND USE THEREOF CARTER, SANDRA DILLAHUNT §102§112DP Non-Final OA Pending Jan 30, 2024
18293515 MULTISPECIFIC ANTIGEN-BINDING PROTEIN AND USE THEREOF CHEONG, CHEOM-GIL §102§112DP Non-Final OA Pending Jan 30, 2024
18576215 ANTI-CD24 ANTIBODY AND USE THEREOF LUNDE, GRACE HENRY §101§102§112DP Non-Final OA Pending Jan 03, 2024
18569312 ANTI-TNFR2 ANTIBODY AND PREPARATION METHOD AND APPLICATION THEREOF LEE, YIE CHIA §101§112 Non-Final OA Pending Dec 12, 2023

Managing Shenghe (China) Biopharmaceutical Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month